跳至主要内容
临床试验/NCT01881620
NCT01881620已完成不适用

PET / Enhanced CT Scan Performance in Cancer (Positron Emission Tomography Combined With Computed Tomography or Vascular Contrast CT Scan). COMBI TEP Study

Institut Bergonié0 个研究点目标入组 109 人开始时间: 2010年3月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
109
主要终点
Inter-observer (B1 and B2) Reproducibility of the PET-CT by Anatomical Regions

研究概览

简要总结

Hypothesis:

The investigators would like to demonstrate that diagnosis performance of PET/CT scan without and with contrast agent (COMBI TEP), are equivalent or better than those of PET/ non enhanced CT scan (PET scan) associated with an enhanced CT scan. This research project is a pilot study given the few available data concerning this imaging exam reproducibility.

This study is a prospective single center study.

详细描述

Hypothesis

We would like to demonstrate that diagnosis performance of PET/CT scan without and with contrast agent (COMBI TEP), are equivalent or better than those of PET/ non enhanced CT scan (PET scan) associated with an enhanced CT scan. This research project is a pilot study given the few available data concerning this imaging exam reproducibility. This study allows us to assess the feasibility of such a large-scale study, but also to evaluate COMBI TEP performance. From these estimates, we can then consider a comparative study to evaluate the performance of COMBI PET.

This study is a prospective single center study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Any patient with a cancerous disease for which PET scan is indicated in the SOR (Standards - Options - Recommendations) FDG PET 2003 updated in 2006 must be included in the trial, in the following locations:
  • •Digestive cancers
  • •Colorectal cancer
  • •Preoperative evaluation in local and metastatic recurrence
  • •Location of recurrences, in case of ACE increase in a previously operated patient.
  • •Esophageal cancer: initial staging.
  • •Pancreatic cancer
  • •Initial staging,
  • •Differential diagnosis with chronic pancreatitis.
  • •Liver cancer: differential diagnosis of liver metastases, cholangiocarcinoma and benign tumors in the case of an isolated hepatic localization.
  • •Digestive Endocrine tumors: staging in case of normal pentetreotide scintigraphy.
  • •Lung cancer
  • •Initial staging,
  • •Diagnosis of lung isolated lesion > 1 cm.
  • •Head and neck cancer
  • •Initial pretreatment staging,
  • •Recurrence diagnosis
  • •Initial staging of Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) and aggressive follicular lymphomas,
  • •Diagnosis of minimal residual disease of HD and aggressive NHL,
  • •Early assessment of treatment response.
  • •Thyroid cancer: suspicion of residual disease or relapse when conventional imaging data are insufficient.
  • •Ovarian cancer recurrence
  • •Age ≥ 18 years.
  • •Chest-abdomen-pelvis enhanced CT scan achieved within 4 weeks before enrollment (with cuts of less than 5 mm).
  • •Woman of childbearing age with negative pregnancy test and / or contraception.
  • •Patient with informed consent signed.
  • •Patient affiliated to social security schemes.

排除标准

  • •Iodine known allergy.
  • •Diabetes, excepted if controlled (hemoglucotest ≤ 1.6 g).
  • •Known renal failure (creatinine clearance <60ml/min).
  • •Indications against Xenetix ®:
  • •Hypersensitivity to Xenetix ® or any of the excipients,
  • •History of an immediate response or delayed cutaneous reaction to Xenetix ® injection.
  • •Thyrotoxicosis.
  • •Pregnant or lactating women.
  • •Unable to undergo medical follow up for geographical, social or psychological reasons,
  • •Private of freedom patient and adult under a legal guardianship or unable to consent.

研究组 & 干预措施

COMBI TEP : PET / enhanced CT scan

Experimental

COMBI TEP : PET / enhanced CT scan

干预措施: COMBI TEP : PET / enhanced CT scan (Device)

结局指标

主要结局

Inter-observer (B1 and B2) Reproducibility of the PET-CT by Anatomical Regions

时间窗: 1 year

The primary endpoint was the inter-observer reproducibility of the interpretation of the combined PET / enhanced CT scan (PET-CT) by anatomical region. Reproducibility was assessed for each of the 5 anatomical regions (thorax, abdomen, pelvis, bone, nervous system). Two independant pairs (B1 and B2), each composed of one nuclear physician and one radiologist interpreted the PET-CT examination and described each of the 5 anatomical régions according to 3 modalities (Presence of suspicious lesion(s); Presence of dubious lesion(s); Absence of suspicious and dubious lesion). The inter-observer reproducibility (inter-pairs of observers) was evaluated for each anatomical region by comparing the interpretations of the two pairs, using the weighted kappa concordance coefficient \[ref = Fleiss J, Levin B, Cho Paik M. Statistical methods for rates and proportions. Third ed. 2003.\].Interpretation by B1 after PET-CT examination (1 month after). Interpretation by B2 at the end of the study

次要结局

  • Inter-observer (B1 and B2) Reproducibility of the PET-CT at a Patient Level(1 year)
  • Inter-observer (N1 and B2) Reproducibility of the PET-CT by Anatomical Regions(1 year)
  • Inter-observer (N1 and B2) Reproducibility of the PET-CT at a Patient Level(1 year)
  • Intra-observer Reproducibility of Injected CT Scan by Anatomical Regions(1 year)
  • Intra-observer Reproducibility of Injected CT Scanat a Patient Level(1 year)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

PET Enhanced CT Scan Performance in Cancer | 临床试验